| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Alkermes Plc (ALKS) has 14 insiders with recent SEC Form 4 filings, including 0 buys and 17 sells. ALKS is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| VP | 225.5K | $10.91M | -2,034 | |
| VP | 109.2K | $5.28M | - | |
| VP | 69.4K | $3.36M | -9,000 | |
| Dir | 43.3K | $2.10M | -44,472 | |
| CFO | 36.7K | $1.77M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2017 | Breyer Robert A | Director | Sell | 4,000 | $60.00 | $240,000.00 | -35.9% | |
| Mar 2, 2017 | Cooke Shane62 | President, Alkermes Plc | Sale+OE | 20,000 | $60.00 | $1,200,000.00 | -22.4% | |
| Mar 1, 2017 | Mitchell Paul J | Director | Sale+OE | 1,500 | $57.06 | $85,590.00 | -15.8% | |
| Feb 16, 2017 | Ehrich Elliot | EVP, R&D &CMO, Alkermes, Inc. | Sale+OE | 11,000 | $56.68 | $623,441.49 | -6.6% | |
| Feb 1, 2017 | Mitchell Paul J | Director | Sale+OE | 1,500 | $54.45 | $81,675.00 | -15.8% | |
| Jan 17, 2017 | Ehrich Elliot | EVP, R&D &CMO, Alkermes, Inc. | Sale+OE | 11,983 | $54.32 | $650,945.32 | -19.1% | |
| Jan 9, 2017 | Cooke Shane62 | President, Alkermes Plc | Sale+OE | 550 | $60.27 | $33,148.50 | -0.9% | |
| Jan 9, 2017 | Stejbach Mark | Svp/ Chief Comm Off, Alks Inc | Sale+OE | 547 | $60.27 | $32,967.69 | -1.6% | |
| Jan 6, 2017 | Ehrich Elliot | EVP, R&D &CMO, Alkermes, Inc. | Sale+OE | 10,000 | $59.44 | $594,425.33 | -4.5% | |
| Jan 6, 2017 | Stejbach Mark | Svp/ Chief Comm Off, Alks Inc | Sale+OE | 9,453 | $60.05 | $567,686.53 | -8.5% |